Scinai Immunotherapeutics Reports Revenue Growth and Narrowing Losses in Q1 2025
Scinai Immunotherapeutics demonstrates financial resilience with increased revenue from CDMO contracts and reduced net losses, signaling potential strategic pivots in its business model.
